Fractyl Health Inc Quick Ratio (GUTS) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Fractyl Health Inc   (NASDAQ: GUTS)

Fractyl Health Inc 's Quick Ratio

GUTS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2026, Quick Ratio fell to 1.82 below Fractyl Health Inc average.

Within Medical Equipment & Supplies industry 60 other companies have achieved higher Quick Ratio than Fractyl Health Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 682 to 1119.

Explain Quick Ratio?
How much Cash & cash equivalents GUTS´s has?
What are GUTS´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/GUTS/financial-strength
https://api.csimarket.com/api/v1/companies/GUTS/fundamentals
https://api.csimarket.com/api/v1/companies/GUTS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
GUTS Quick Ratio (Sep 30 2026)
Q3
(Jun 30 2026)
Q2
(Mar 31 2026)
Q1
(Dec 31 2025)
Q4
(Sep 30 2025)
Q3
Y / Y Current Liabilities Change -7.16 %
Y / Y Cash & cash equivalent Change -59.42 %
Quick Ratio MRQ 1.82
GUTS's Total Ranking # 1119
Seq. Current Liabilities Change 10.22 %
Seq. Cash & cash equivalent Change -33.15 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 61
Healthcare Sector # 406
Overall Market # 1119


Quick Ratio Statistics
High Average Low
25.04 6.35 1.02
(Dec 31 2025)   (Jun 30 2025)




Financial Statements
Fractyl Health Inc 's Current Liabilities $ 17 Millions Visit GUTS's Balance sheet
Fractyl Health Inc 's Cash & cash equivalent $ 32 Millions Visit GUTS's Balance sheet
Source of GUTS's Sales Visit GUTS's Sales by Geography


Cumulative Fractyl Health Inc 's Quick Ratio

GUTS's Quick Ratio for the trailling 12 Months

GUTS Quick Ratio

(Sep 30 2026)
12 Months
(Jun 30 2026)
12 Months
(Mar 31 2026)
12 Months
(Dec 31 2025)
12 Months
(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -35.91 %
Y / Y Cash & cash equivalent TTM Growth 6.61 %
Quick Ratio TTM 4.32
Total Ranking TTM # 477
Seq. Current Liabilities TTM Growth -2.52 %
Seq. Cash & cash equivalent TTM Growth -17.12 %


On the trailing twelve months basis In spite of the year on year decrease in GUTS's Current Liabilities to $17.35 millions, cumulative Quick Ratio to 4.32 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Medical Equipment & Supplies industry 194 other companies have achieved higher Quick Ratio than Fractyl Health Inc . While Quick Ratio overall ranking has improved so far to 3646, from total ranking during the twelve months ending second quarter 2026 at 3764.

Explain Quick Ratio?
How much Cash & cash equivalents GUTS´s has?
What are GUTS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Medical Equipment & Supplies Industry # 195
Healthcare Sector # 869
Within the Market #


trailing twelve months Quick Ratio Statistics
High Average Low
5.96 3.7 2.65
(Dec 31 2024)   (Sep 30 2025)




Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Medical Equipment & Supplies Industry Quick RatioSep 30 2026 MRQ Cash & cash equivalentSep 30 2026 MRQ Current Liabilities
Beyond Air Inc   4.69 $ 17.121  Millions$ 3.647  Millions
Clearpoint Neuro Inc   4.68 $ 46.184  Millions$ 9.869  Millions
Cvrx inc   4.67 $ 58.746  Millions$ 12.583  Millions
Heartbeam Inc   4.47 $ 6.065  Millions$ 1.358  Millions
Dexcom Inc   4.25 $ 964.800  Millions$ 227.000  Millions
Innovative Eyewear Inc   3.86 $ 3.197  Millions$ 0.829  Millions
Sight Sciences Inc   3.84 $ 77.402  Millions$ 20.137  Millions
Bluejay Diagnostics Inc  3.83 $ 7.380  Millions$ 1.927  Millions
Alpha Pro Tech Ltd   3.78 $ 25.546  Millions$ 6.750  Millions
Hyperfine Inc   3.60 $ 37.872  Millions$ 10.532  Millions
Capsovision Inc   3.55 $ 21.757  Millions$ 6.124  Millions
Profound Medical Corp   3.41 $ 33.343  Millions$ 9.771  Millions
Rxsight Inc   3.40 $ 254.683  Millions$ 74.952  Millions
Omada Health Inc   3.23 $ 243.151  Millions$ 75.379  Millions
Transmedics Group Inc   3.22 $ 492.962  Millions$ 152.857  Millions
Trisalus Life Sciences Inc   3.15 $ 41.057  Millions$ 13.014  Millions
Procept Biorobotics Corporation  3.10 $ 218.369  Millions$ 70.353  Millions
Carlsmed Inc   3.08 $ 56.207  Millions$ 18.237  Millions
Neuropace Inc   3.08 $ 49.431  Millions$ 16.070  Millions
Outset Medical Inc   3.07 $ 136.627  Millions$ 44.453  Millions
Sharps Technology Inc   2.82 $ 7.478  Millions$ 2.650  Millions
Edwards Lifesciences Corporation  2.81 $ 4,683.700  Millions$ 1,664.300  Millions
Mimedx Group Inc   2.81 $ 120.791  Millions$ 43.031  Millions
Streamex Corp   2.80 $ 26.248  Millions$ 9.382  Millions
Pulse Biosciences Inc   2.74 $ 36.725  Millions$ 13.395  Millions
Staar Surgical Co  2.73 $ 206.414  Millions$ 75.541  Millions
Medinotec Inc   2.68 $ 2.584  Millions$ 0.963  Millions
Glaukos Corp  2.66 $ 337.478  Millions$ 126.726  Millions
Pulmonx Corporation  2.57 $ 53.245  Millions$ 20.739  Millions
Beta Bionics Inc   2.48 $ 81.551  Millions$ 32.836  Millions

Date modified: 2026-11-13T08:37:07+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.